DefiniGEN are a University of Cambridge company supplying optimised human cells for preclinical drug discovery and disease modelling using human Induced Pluripotent Stem Cells (hIPSC). The platform technology - OptiDIFF™ is a system for the optimised generation of key cell types including hepatocytes and pancreatic cells. These cell products deliver major benefits for the pharmaceutical sector by enabling more accurate predictions of the efficacy and safety of compounds through the drug development process. The use of fully defined conditions also enables the utilisation of the platform in the development of regenerative medicine therapies.
Key staff involved in EBiSC
Dr Marcus Yeo (CEO) –
Dr Anita Marguerie (Technical Manager) –
Louise Wray (Toxicology Application Dev. Manager) –
Dr Adriana Ordonez (Disease model Dev. Manager ) –
More information: www.definigen.com »